Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polyethylene Glycol Loxenatide plus exercise in sarcopenic type 2 diabetes
ChiCTR2300071939Phase 4Recruiting
- Sponsor
- Tongji Hospital
- Start
- Jun 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial of polyethylene glycol loxenatide in type 2 diabetes mellitus (T2DM) and Sarcopenia (2 arms), sponsored by Tongji Hospital. Primary endpoint: muscle mass. Started Jun 2022; status: recruiting.
02
Drugs
polyethylene glycol loxenatide
03
Conditions
type 2 diabetes mellitus (T2DM)Sarcopenia
Beyond the preview
Go deeper on ChiCTR2300071939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071939.